Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Thank you for selecting your broker
We are redirecting you to the Broker Center now
Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you
Thank you for your submission, we hope you enjoy your experience
ALERT

FREE Webinar for FA’s and RIA’s — Reserve Your Seat Now!

Mutualfunds logo

JFNCX Janus Global Life Sciences C

  • Fund
  • JFNCX
  • Price as of: Dec 02, 2016
  • $42.55
  • + $0.31
  • + 0.73%
  • Category
  • Health & Biotech Equities

JFNCX - Profile

Vitals

  • YTD Return -12.7%
  • 3 Yr Annualized Return 10.4%
  • 5 Yr Annualized Return 19.0%
  • Net Assets $3.4 B
  • Holdings in Top 10 27.7%

52 WEEK LOW AND HIGH

$42.55
$39.17
$53.57

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.76%

SALES FEES

  • Front Load N/A
  • Deferred Load 1.00%

BROKERAGE FEES

  • Turnover 47.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

STANDARD (TAXABLE)

$2,500

IRA

N/A

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return -12.7%
  • 3 Yr Annualized Total Return 10.4%
  • 5 Yr Annualized Total Return 19.0%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.96%
DIVIDENDS
  • Dividend Yield N/A
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name Janus Global Life Sciences Fund
  • Fund Family Name Janus
  • Inception Date Jul 06, 2009
  • Shares Outstanding N/A
  • Share Class C
  • Currency USD
  • Domiciled Country United States
  • Manager Andrew Acker

JFNCX - Performance

Return Ranking - Trailing

Period JFNCX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD -12.7% -30.9% 7.4% 63.39% 4
1 Yr -13.2% -23.6% 18.4% 78.38% 4
3 Yr 10.4% * -7.5% 17.2% 26.85% 2
5 Yr 19.0% * 9.3% 21.9% 21.36% 2
10 Yr 10.7% * 6.1% 14.3% 36.36% 2

* Annualized


Return Ranking - Calendar

Period JFNCX Return Category Return Low Category Return High Rank in Category (%) Quintile
2015 -2.0% -20.4% 13.8% 46.36% 3
2014 20.4% -5.9% 31.5% 28.18% 2
2013 42.0% 0.0% 65.2% 43.12% 3
2012 19.0% -5.3% 36.5% 32.04% 2
2011 6.4% -15.5% 18.8% 39.22% 3

Total Return Ranking - Trailing

Period JFNCX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD -12.7% -23.3% 7.4% 65.77% 4
1 Yr -14.0% -27.5% 16.2% 69.09% 4
3 Yr 10.4% * -14.2% 17.0% 21.30% 2
5 Yr 19.0% * 9.0% 21.9% 17.48% 1
10 Yr 10.7% * 6.1% 14.3% 34.34% 2

* Annualized


Total Return Ranking - Calendar

Period JFNCX Return Category Return Low Category Return High Rank in Category (%) Quintile
2015 8.0% -16.6% 20.7% 46.79% 3
2014 44.2% -5.8% 55.3% 15.60% 1
2013 100.1% 0.0% 398.7% 20.37% 1
2012 58.5% -5.1% 475.8% 21.00% 2
2011 17.4% -10.2% 2296.2% 40.21% 3

NAV & Total Return History

JFNCX - Holdings

Filings data as of: Sep 30, 2016

Concentration Analysis

JFNCX Category Low Category High JFNCX % Rank Quintile
Net Assets 3.4 B 20.5 M 43.6 B 7.14% 1
Number of Holdings 93 31 345 12.50% 2
Net Assets in Top 10 1.06 B 9.55 M 20.9 B 11.61% 2
Weighting of Top 10 27.7% 21.8% 71.5% 33.04% 5

Top 10 Holdings

  1. Celgene Corp 2.78%
  2. Amgen Inc 3.47%
  3. Allergan PLC 2.39%
  4. Sanofi SA 2.47%
  5. Aetna Inc 2.58%
  6. Bristol-Myers Squibb Company 2.61%
  7. Eli Lilly and Co 3.27%
  8. Pfizer Inc 2.99%
  9. AstraZeneca PLC 2.69%
  10. Shire PLC ADR 2.49%

Asset Allocation

Weighting Category Low Category High JFNCX % Rank Quintile
Stocks
96.72% 82.12% 103.35% 23.21% 4
Other
1.77% -3.35% 10.27% 6.25% 1
Cash
1.13% 0.00% 16.35% 15.18% 3
Convertible Bonds
0.38% 0.00% 0.38% 0.89% 1
Preferred Stocks
0.00% 0.00% 0.96% 4.46% 3
Bonds
0.00% 0.00% 1.91% 5.36% 3

Stock Sector Breakdown

Weighting Category Low Category High JFNCX % Rank Quintile
Healthcare
92.28% 13.15% 99.87% 20.54% 3
Technology
3.56% 0.00% 64.83% 5.36% 1
Industrials
0.89% 0.00% 13.35% 7.14% 2
Financial Services
0.00% 0.00% 1.00% 6.25% 3
Utilities
0.00% 0.00% 1.10% 1.79% 3
Real Estate
0.00% 0.00% 1.97% 2.68% 3
Energy
0.00% 0.00% 0.00% 0.89% 3
Communication Services
0.00% 0.00% 1.73% 1.79% 3
Consumer Defense
0.00% 0.00% 2.38% 12.50% 4
Consumer Cyclical
0.00% 0.00% 3.21% 7.14% 3
Basic Materials
0.00% 0.00% 4.92% 4.46% 3

Stock Geographic Breakdown

Weighting Category Low Category High JFNCX % Rank Quintile
US
78.82% 60.81% 99.87% 28.57% 5
Non US
17.90% 0.00% 41.10% 7.14% 2

JFNCX - Expenses

Operational Fees

JFNCX Fees (% of AUM) Category Low Category High Rank in Category (%) Quintile
Expense Ratio 1.76% 0.10% 4.31% 24.11% 4
Management Fee 0.64% 0.08% 1.25% 13.39% 2
12b-1 Fee 1.00% 0.00% 1.00% 1.28% 4
Administrative Fee N/A 0.01% 0.40% N/A N/A

Sales Fees

JFNCX Fees (% of AUM) Category Low Category High JFNCX Rank Quintile
Front Load N/A 3.50% 5.75% N/A N/A
Deferred Load 1.00% 1.00% 5.00% 12.50% 2

Trading Fees

JFNCX Fees (% of AUM) Category Low Category High JFNCX Rank Quintile
Max Redemption Fee N/A 0.75% 2.00% N/A N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

JFNCX Fees (% of AUM) Category Low Category High JFNCX Rank Quintile
Turnover 47.00% 7.00% 249.00% 15.18% 3

JFNCX - Distributions

Dividend Yield Analysis

JFNCX Category Low Category High JFNCX % Rank Quintile
Dividend Yield N/A 0.01% 0.94% N/A N/A

Dividend Distribution Analysis

JFNCX Category Low Category High Category Mode
Dividend Distribution Frequency Annually Annually Quarterly Annually

Dividend Payout History


Net Income Ratio Analysis

JFNCX Category Low Category High JFNCX % Rank Quintile
Net Income Ratio -0.96% -2.22% 1.40% 52.68% 4

Capital Gain Distribution Analysis

JFNCX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

JFNCX - Managers

Andrew Acker

Manager

Start Date

May 01, 2007

Tenure

9.51

Tenure Rank

10.0%

Andrew Acker, CFA, is Executive Vice President and Portfolio Manager , which he has managed since May 2007. Mr. Acker is also Portfolio Manager of other Janus accounts and performs duties as a research analyst. He joined Janus Capital in 1999 as a securities analyst. Mr. Acker holds a Bachelor of Science degree (magna cum laude) in Biochemical Sciences from Harvard College where he was a member of Phi Beta Kappa. He also holds a Master’s degree in Business Administration with honors from Harvard Business School. Mr. Acker holds the Chartered Financial Analyst designation.


Ethan Lovell

Manager

Start Date

Jan 12, 2016

Tenure

0.8

Tenure Rank

20.5%

Ethan Lovell is an equity research analyst primarily focusing on the global pharmaceutical industry. Mr. Lovell also serves as a co-team leader of the health care sector research team and is assistant portfolio manager on the Janus Global Life Sciences strategy. Mr. Lovell joined Janus Capital as a research analyst in August 2007. Mr. Lovell holds a Bachelor of Arts degree from Bowdoin College with a double major in Chemistry and Economics and a Master’s degree in Business Administration from Tulane University.


Tenure Analysis

Category Low

0.0

Category High

19.1

Category Average

8.78

Category Mode

4.8